| Overview |
| bs-11887R-Cy5.5 |
| MPP5/PALS1 Polyclonal Antibody, Cy5.5 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Dog, Cow, Sheep, Pig, Horse, Chicken, Rabbit |
| Specifications |
| Cy5.5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human MPP5/PALS1 |
| 201-300/675 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Cytoplasm, Cell membrane |
| FLJ12615; MAGUK p55 subfamily member 5; Membrane protein palmitoylated 5; MPP 5; MPP5; MPP5_HUMAN; PALS 1; PALS1; Protein associated with Lin-7; Stardust Drosophila; Stardust. |
| Two highly conserved complexes are responsible for the assembly of tight junctions, the Crumbs-Pals1-Patj complex and the Cdc42-Par6-Par3-aPKC complex. Tight junctions assist in the formation of polarity in the epithelia by establishing a barrier to separate apical and basolateral membranes. Pals1, importantly, mediates interaction between the two complexes via interaction with Par6. Loss of Pals1 function results in delayed polarization, decreased transepithelial electrical resistance and an inability to form lumenal cysts. Because tumors exhibit perturbations in epithelial polarity, Pals1 presents a new potential target in the study of carcinogenesis. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz